Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 4/20 | 0.63 |
| ▸ | CTSL | P07711 | 4/20 | 0.63 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | MYC | P01106 | 1/20 | 0.55 |
| ▸ | MAX | P61244 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL750963 | 0.89 | CTSV (0.58) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL29368594 | 0.89 | ALDH1A1 (0.63) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL965943 | 0.89 | ALDH1A1 (0.63) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL16004968 | 0.89 | ABCB1 (0.59) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL9658186 | 0.89 | CTSV (0.58) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL30082870 | 0.89 | MYC (0.67) | CTSVCTSLABCB1MEN1KMT2A | |
| SCHEMBL528177 | 0.89 | MYC (0.67) | CTSVCTSLABCB1MEN1KMT2A | |
| SCHEMBL7516329 | 0.88 | NR4A2 (0.55) | CTSVCTSLPOLBMRGPRX4CASP6 | |
| SCHEMBL11091089 | 0.88 | CTSV (0.57) | CTSVCTSLABCB1MEN1MAPT | |
| SCHEMBL1455427 | 0.87 | MAPT (0.62) | CTSVCTSLMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110183348-B | N- (3-nitro-4-alkoxy benzoyl) amino acid compound, preparation method and application thereof | 中国医科大学 | 2022-06-03 | — | — | CN | disclosed |
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED | 2021-11-11 | — | — | US | disclosed |
| WO-2021222174-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS INCORPORATED (US) | 2021-11-04 | — | — | WO | disclosed |
| US-10301598-B2 | Low-molecular-compound for improving production, maintenance and proliferation of pluripotent stem cells, composition comprising the same, and culture method | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2019-05-28 | — | — | US | disclosed |
| US-20170159023-A1 | NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2017-06-08 | — | — | US | disclosed |
| EP-2774918-B1 | NOVEL LOW-MOLECULAR WEIGHT COMPOUND FOR PROMOTING PLURIPOTENT STEM CELL GENERATION, MAINTENANCE, AND PROLIFERATION, AND COMPOSITION AND CULTURING METHOD CONTAINING SAME | KOREA RES INST BIOSCIENCE & BIOTECHNOLOGY (KR) | 2017-03-22 | — | — | EP | disclosed |
| US-9587225-B2 | Low-molecular-compound for improving production, maintenance and proliferation of pluripotent stem cells, composition comprising the same, and culture method | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2017-03-07 | — | — | US | disclosed |
| US-20150159142-A1 | NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD | Korea Reasearch Institute of Bioscience and Biotechnology (KR) | 2015-06-11 | — | — | US | disclosed |
| EP-2774918-A1 | NOVEL LOW-MOLECULE COMPOUND FOR PROMOTING PLURIPOTENT STEM CELL GENERATION, MAINTENANCE, AND PROLIFERATION, AND COMPOSITION AND CULTURING METHOD CONTAINING SAME | Korea Research Institute of Bioscience and Biotechology (KR) | 2014-09-10 | — | — | EP | disclosed |
| CN-101454285-B | Oxadiazole derivatives as comt inhibitors | PORTELA & CA SA | 2012-06-27 | — | — | CN | disclosed |
| CN-101454285-A | Oxadiazole derivatives as comt inhibitors | PORTELA & CA SA (PT) | 2009-06-10 | — | — | CN | disclosed |
| CN-101379044-A | Heterobicyclic sulfonamide derivatives for the treatment of diabetes | HOFFMANN LA ROCHE (CH) | 2009-03-04 | — | — | CN | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
| WO-2007017092-A1 | SUBSTITUTED 4-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007017092-A1 | SUBSTITUTED 4-BENZYLOXY-BENZOIC ACID AMIDE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-5529998-A | ANTIBACTERIAL MEDICAMENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1996-06-25 | — | — | US | disclosed |
| CN-1122803-A | Benzoxazolyl- and benzothiazolyloxazolidinones | BAYER AG (DE) | 1996-05-22 | — | — | CN | disclosed |
| EP-0697412-A1 | Benzoxazolyl- and benzo-thiazolyl-oxazolidinones | BAYER AG (DE) | 1996-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210346405-A1 | BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS | BCL2, BCL2L2, BCL2L1 | CTSV 378/4885CTSL 522/4885ABCB1 127/4885 |
| US-20150159142-A1 | NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD | MYC, MYCBP, HES1 | CTSV 4535/4885CTSL 3890/4885ABCB1 3802/4885 |
| US-10301598-B2 | Low-molecular-compound for improving production, maintenance and proliferation of pluripotent stem cells, composition comprising the same, and culture method | AANAT, MKI67, VIM | CTSV 4765/4885CTSL 4700/4885ABCB1 1464/4885 |
| US-20170159023-A1 | NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD | AANAT, MKI67, ACP1 | CTSV 4773/4885CTSL 4674/4885ABCB1 1604/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CTSV 2644/4885CTSL 2313/4885ABCB1 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.